FY2024 EPS Estimates for Phibro Animal Health Co. Lifted by Analyst (NASDAQ:PAHC)

Phibro Animal Health Co. (NASDAQ:PAHC) – Analysts at Zacks Research upped their FY2024 EPS estimates for Phibro Animal Health in a research note issued on Tuesday, April 23rd. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $1.13 for the year, up from their prior forecast of $1.12. The consensus estimate for Phibro Animal Health’s current full-year earnings is $1.12 per share. Zacks Research also issued estimates for Phibro Animal Health’s Q4 2024 earnings at $0.37 EPS, Q2 2025 earnings at $0.34 EPS, Q4 2025 earnings at $0.40 EPS, FY2025 earnings at $1.21 EPS and Q3 2026 earnings at $0.32 EPS.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings results on Wednesday, February 7th. The company reported $0.33 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.06. Phibro Animal Health had a return on equity of 16.67% and a net margin of 1.51%. The company had revenue of $249.90 million for the quarter, compared to analysts’ expectations of $242.91 million.

Separately, StockNews.com upgraded shares of Phibro Animal Health from a “hold” rating to a “buy” rating in a research report on Tuesday, April 9th.

Phibro Animal Health Price Performance

Shares of NASDAQ:PAHC opened at $12.44 on Wednesday. Phibro Animal Health has a 12 month low of $9.40 and a 12 month high of $15.96. The stock has a market cap of $503.82 million, a price-to-earnings ratio of 34.56, a PEG ratio of 5.02 and a beta of 0.75. The stock’s 50 day moving average price is $12.82 and its 200 day moving average price is $11.77. The company has a debt-to-equity ratio of 1.66, a current ratio of 3.12 and a quick ratio of 1.60.

Institutional Investors Weigh In On Phibro Animal Health

Several institutional investors and hedge funds have recently modified their holdings of the business. Brandes Investment Partners LP lifted its position in Phibro Animal Health by 38.5% during the 3rd quarter. Brandes Investment Partners LP now owns 1,873,300 shares of the company’s stock worth $23,922,000 after acquiring an additional 520,697 shares during the last quarter. Wellington Management Group LLP lifted its position in Phibro Animal Health by 165.9% during the 4th quarter. Wellington Management Group LLP now owns 164,764 shares of the company’s stock worth $1,908,000 after acquiring an additional 102,793 shares during the last quarter. GSA Capital Partners LLP lifted its position in Phibro Animal Health by 227.0% during the 3rd quarter. GSA Capital Partners LLP now owns 81,647 shares of the company’s stock worth $1,043,000 after acquiring an additional 56,676 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Phibro Animal Health by 290.2% during the 4th quarter. BNP Paribas Financial Markets now owns 73,287 shares of the company’s stock worth $849,000 after purchasing an additional 54,506 shares during the period. Finally, Brandywine Global Investment Management LLC increased its holdings in shares of Phibro Animal Health by 21.1% during the 3rd quarter. Brandywine Global Investment Management LLC now owns 257,200 shares of the company’s stock worth $3,284,000 after purchasing an additional 44,900 shares during the period. Institutional investors and hedge funds own 99.34% of the company’s stock.

Phibro Animal Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, March 27th. Investors of record on Wednesday, March 6th were paid a $0.12 dividend. This represents a $0.48 annualized dividend and a dividend yield of 3.86%. The ex-dividend date of this dividend was Tuesday, March 5th. Phibro Animal Health’s payout ratio is presently 133.33%.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.